BACKGROUND: Endogenous sex hormone levels are associated with risks of breast cancer overall and estrogen receptor (ER)-positive breast tumors; however, their associations with ER-negative tumors remain unclear. METHODS: In a case-cohort study within the Women's Health Initiative Observational Study among postmenopausal women aged 50-79 years, we examined associations between endogenous testosterone and estradiol levels and the risks of ER-negative and ER-positive breast cancers. Serum levels of bioavailable testosterone and estradiol were assessed at the baseline visit in 317 invasive breast cancer case subjects and in a subcohort of 594 women. Bioavailable sex hormone levels were calculated using the total hormone level and the sex hormone-binding globulin concentration (measured by radioimmunoassays and a chemiluminescent immunoassay, respectively). Cox proportional hazards regression was used for statistical analysis. All statistical tests were two-sided. RESULT: The unadjusted absolute rates of ER-negative breast cancer for testosterone quartiles 1-4 were 0.34, 0.20, 0.23, and 0.21 per 10,000 person-years, respectively. Compared with women in the lowest quartile of testosterone level, those in quartile 2 had a 56% lower risk of ER-negative cancer (hazard ratio [HR] = 0.44, 95% confidence interval [CI] = 0.23 to 0.85), those in quartile 3 had a 45% lower risk (HR = 0.55, 95% CI = 0.30 to 1.01), and those in quartile 4 had a 49% lower risk (HR = 0.51, 95% CI = 0.28 to 0.94), independent of other risk factors. Estradiol level was not associated with ER-negative breast cancer. ER-positive breast cancer risk increased with higher testosterone levels (P(trend) = .04), but this trend was not statistically significant after adjustment for estradiol (P(trend) = .15). ER-positive cancer risk was approximately twofold higher in women with estradiol levels in quartiles 2-4 compared with women in quartile 1, independent of risk factors. CONCLUSION: Higher serum levels of bioavailable testosterone are associated with lower risks of ER-negative breast cancer in postmenopausal women.
BACKGROUND: Endogenous sex hormone levels are associated with risks of breast cancer overall and estrogen receptor (ER)-positive breast tumors; however, their associations with ER-negative tumors remain unclear. METHODS: In a case-cohort study within the Women's Health Initiative Observational Study among postmenopausal women aged 50-79 years, we examined associations between endogenous testosterone and estradiol levels and the risks of ER-negative and ER-positive breast cancers. Serum levels of bioavailable testosterone and estradiol were assessed at the baseline visit in 317 invasive breast cancer case subjects and in a subcohort of 594 women. Bioavailable sex hormone levels were calculated using the total hormone level and the sex hormone-binding globulin concentration (measured by radioimmunoassays and a chemiluminescent immunoassay, respectively). Cox proportional hazards regression was used for statistical analysis. All statistical tests were two-sided. RESULT: The unadjusted absolute rates of ER-negative breast cancer for testosterone quartiles 1-4 were 0.34, 0.20, 0.23, and 0.21 per 10,000 person-years, respectively. Compared with women in the lowest quartile of testosterone level, those in quartile 2 had a 56% lower risk of ER-negative cancer (hazard ratio [HR] = 0.44, 95% confidence interval [CI] = 0.23 to 0.85), those in quartile 3 had a 45% lower risk (HR = 0.55, 95% CI = 0.30 to 1.01), and those in quartile 4 had a 49% lower risk (HR = 0.51, 95% CI = 0.28 to 0.94), independent of other risk factors. Estradiol level was not associated with ER-negative breast cancer. ER-positive breast cancer risk increased with higher testosterone levels (P(trend) = .04), but this trend was not statistically significant after adjustment for estradiol (P(trend) = .15). ER-positive cancer risk was approximately twofold higher in women with estradiol levels in quartiles 2-4 compared with women in quartile 1, independent of risk factors. CONCLUSION: Higher serum levels of bioavailable testosterone are associated with lower risks of ER-negative breast cancer in postmenopausal women.
Authors: M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark Journal: J Natl Cancer Inst Date: 1998-09-16 Impact factor: 13.506
Authors: A Zeleniuch-Jacquotte; P Toniolo; M Levitz; R E Shore; K L Koenig; S Banerjee; P Strax; B S Pasternack Journal: Cancer Epidemiol Biomarkers Prev Date: 1995-12 Impact factor: 4.254
Authors: A Zeleniuch-Jacquotte; R E Shore; K L Koenig; A Akhmedkhanov; Y Afanasyeva; I Kato; M Y Kim; S Rinaldi; R Kaaks; P Toniolo Journal: Br J Cancer Date: 2004-01-12 Impact factor: 7.640
Authors: Carol J Fabian; Lauren Nye; Kandy R Powers; Jennifer L Nydegger; Amy L Kreutzjans; Teresa A Phillips; Trina Metheny; Onalisa Winblad; Carola M Zalles; Christy R Hagan; Merit L Goodman; Byron J Gajewski; Devin C Koestler; Prabhakar Chalise; Bruce F Kimler Journal: Cancer Prev Res (Phila) Date: 2019-08-16
Authors: Po-Yin Chang; David Feldman; Marcia L Stefanick; Donald P McDonnell; Bonne M Thompson; Jeffrey G McDonald; Jennifer S Lee Journal: J Bone Miner Res Date: 2018-12-07 Impact factor: 6.741
Authors: Xuehong Zhang; A Heather Eliassen; Rulla M Tamimi; Aditi Hazra; Andrew H Beck; Myles Brown; Laura C Collins; Bernard Rosner; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-04-08 Impact factor: 4.254
Authors: Niki L Dimou; Nikos Papadimitriou; Dipender Gill; Sofia Christakoudi; Neil Murphy; Marc J Gunter; Ruth C Travis; Tim J Key; Renee T Fortner; Philip C Haycock; Sarah J Lewis; Kenneth Muir; Richard M Martin; Konstantinos K Tsilidis Journal: Int J Epidemiol Date: 2019-06-01 Impact factor: 7.196
Authors: Kristin L Campbell; Karen E Foster-Schubert; Catherine M Alfano; Chia-Chi Wang; Ching-Yun Wang; Catherine R Duggan; Caitlin Mason; Ikuyo Imayama; Angela Kong; Liren Xiao; Carolyn E Bain; George L Blackburn; Frank Z Stanczyk; Anne McTiernan Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Ghada N Farhat; Neeta Parimi; Rowan T Chlebowski; Joann E Manson; Garnet Anderson; Alison J Huang; Eric Vittinghoff; Jennifer S Lee; Andrea Z Lacroix; Jane A Cauley; Rebecca Jackson; Deborah Grady; Dorothy S Lane; Lawrence Phillips; Michael S Simon; Steven R Cummings Journal: J Natl Cancer Inst Date: 2013-09-16 Impact factor: 13.506
Authors: Xuehong Zhang; Shelley S Tworoger; A Heather Eliassen; Susan E Hankinson Journal: Breast Cancer Res Treat Date: 2013-01-03 Impact factor: 4.872
Authors: Melanie R Rutkowski; Nikolaos Svoronos; Alfredo Perales-Puchalt; Jose R Conejo-Garcia Journal: Adv Cancer Res Date: 2015-05-21 Impact factor: 6.242